Estudios originales
Published on 9 de enero de 2026 | http://doi.org/10.5867/medwave.2026.01.3049
Identification and susceptibility profile of microorganisms isolated directly from urine in a cross-sectional study using matrix-assisted laser desorption/ionization time-of-flight and Phoenix M50
Back to article
Results of antimicrobial suceptibility testing compliance for according to Cumitech 31A criteria.
| Amikacin | 26 | 100 | 100 | 0 | 0 | 0 | 0 |
| Amoxicillin-Clavulanic acid | 21 | 95.2 | 95.2 | 4.8 | 0 | 4.8 | 0 |
| Ampicilin | 26 | 100 | 100 | 0 | 0 | 0 | 0 |
| Cefazolin | 26 | 88.5 | 96.2 | 11.5 | 0 | 11.5 | 0 |
| Cefepime | 26 | 96.2 | 96.2 | 0 | 3.8 | 3.8 | 0 |
| Cefoxitin | 26 | 84.6 | 100 | 11.5 | 3.8 | 15.3 | 0 |
| Ceftazidime | 26 | 100 | 100 | 0 | 0 | 0 | 0 |
| Ceftriaxone | 26 | 100 | 100 | 0 | 0 | 0 | 0 |
| Cefuroxime | 22 | 100 | 100 | 0 | 0 | 0 | 0 |
| Ciprofloxacin | 26 | 92.3 | 100 | 7.7 | 0 | 7.7 | 0 |
| Ertapenem | 24 | 95.8 | 95.8 | 0 | 4.2 | 4.2 | 0 |
| Gentamicin | 26 | 96.2 | 96.2 | 0 | 3.8 | 3.8 | 0 |
| Imipenem | 25 | 96 | 92 | 0 | 4 | 4 | 0 |
| Levofloxacin | 26 | - | 100 | 0 | 0 | 0 | 0 |
| Meropenem | 26 | 88.5 | 88.5 | 3.8 | 7.7 | 11.5 | 0 |
| Nitrofurantoin | 21 | 85.7 | 100 | 9.5 | 0 | 9.5 | 4.8 |
| Norfloxacin | 22 | 100 | 100 | 0 | 0 | 0 | 0 |
| Piperacillin-Tazobactam | 26 | 88.5 | 92.3 | 3.8 | 3.8 | 7.6 | 3.8 |
| Tetracycline | 21 | 95.2 | 95.2 | 0 | 0 | 0 | 4.8 |
| Trimethoprim-Sulfamethoxazole | 26 | 96.2 | 100 | 0 | 0 | 0 | 3.8 |
Categorical agreement (CA), essential agreement (EA), minor errors (mE), major errors (ME), and very major errors (VME).
Source: Prepared by the authors of this study.